发明公开
EP2281561A2 Use of LCK inhibitors for treatment of immunologic diseases
审中-公开
Verwendung von LCK-Hemmern zur Behandlung von Immunerkrankungen
- 专利标题： Use of LCK inhibitors for treatment of immunologic diseases
- 专利标题（中）： Verwendung von LCK-Hemmern zur Behandlung von Immunerkrankungen
-
申请号： EP10184940.4申请日： 2003-08-11
-
公开(公告)号： EP2281561A2公开(公告)日： 2011-02-09
- 发明人: Roth, Gerald Jürgen , Hauptmann, Rudolf , Hilberg, Frank , Colbatzky, Florian , Ernst, Steffen , Heckel, Armin , Stefanic, Martin, Friedrich , Walter, Rainer
- 申请人： Boehringer Ingelheim Pharma GmbH & Co. KG
- 申请人地址： Binger Straße 173 55216 Ingelheim am Rhein DE
- 专利权人： Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人： Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人地址： Binger Straße 173 55216 Ingelheim am Rhein DE
- 代理机构： Hammann, Heinz
- 优先权： DE10237423 20020816
- 主分类号： A61K31/404
- IPC分类号： A61K31/404 ; A61K31/454 ; A61K31/517 ; A61K45/06 ; A61P37/00 ; A61P37/06 ; A61P29/00 ; A61P1/00 ; A61P3/10 ; A61P17/06 ; A61P11/06 ; A61P25/00
摘要：
The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
公开/授权文献
- EP2281561A3 Use of LCK inhibitors for treatment of immunologic diseases 公开/授权日：2012-05-09
信息查询
IPC分类:
